Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: Meta-analysis of randomized controlled studies

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Naing, Cho ^a,b   Racloz, Vanessa ^a   Whittaker, Maxine Anne ^a   Aung, Kyan ^b   Reid, Simon Andrew ^a   Mak, Joon Wah ^b   Tanner, Marcel ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE PLUS MEFLOQUINE; CHLOROQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; NAPHTHOQUINE; PRIMAQUINE; PYRIMETHAMINE PLUS SULFADOXINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; FEVER; HUMAN; MALARIA FALCIPARUM; META ANALYSIS; PARASITE CLEARANCE; PATIENT COMPLIANCE; PLASMODIUM VIVAX MALARIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; VOMITING;

ANTIMALARIALS; ARTEMISININS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALARIA, VIVAX; MALE; PLASMODIUM VIVAX; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84891752316     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078819     Document Type: Article

References (59)

1. Mendis K, Sina BJ, Marchesini P, Carter R (2001) The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64: 97-106. PubMed: 11425182.
2. Sina B (2002) Focus on Plasmodium vivax. Trends Parasitol 18: 287-289. doi:10.1016/S1471-4922(02)02329-2. PubMed: 12379943.
3. World Health Organization (WHO) (2002) Monitoring antimalarial drug resistance (Report of a WHO consultation 3rd-5th December 2001). Geneva (WHO/CDS/CSR/EPH/2002.17).
4. Price RN, Tjitra M, Guerra CA, Yeung S, White NJ et al. (2007) Vivax malaria: neglected and not benign. Am J Trop Med Hyg 77: 79-87. PubMed: 18165478.
5. Nosten F, Mcgready R, Simpson JA (1999) Effects of Plasmodium vivax malaria in pregnancy. Lancet 354: 546-549. doi:10.1016/ S0140-6736(98)09247-2. PubMed: 10470698.
6. de Santana Filho FS, Arcanjo AR, Chehuan YM, Costa MR, Martinez-Espinosa FE et al. (2007) Chloroquine resistant Plasmodium vivax, Brazilian Amazon. Emerg Infect Dis 13: 1125-1126. doi:10.3201/eid1307.061386. PubMed: 18214203.
7. Teka H, Petros B, Yamuah L, Tesfaye G, Elhassan I et al. (2008) Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar J 7: 220. doi:10.1186/1475-2875-7-220. PubMed: 18959774.
8. Marlar T, Myat PK, Aye YS, Khaing KG, Ma S et al. (1995) Development of resistance to chloroquine by Plasmodium vivax in Myanmar. Trans R Soc Trop Med Hyg 89: 307-308. doi: 10.1016/0035-9203(95)90556-1. PubMed: 7660445.
9. Kurcer MA, Simsek Z, Zeyrek FY, Atay S, Celik H et al. (2004) Efficacy of chloroquine in the treatment of Plasmodium vivax malaria in Turkey. Ann Trop Med Parasitol 98: 447-451. doi: 10.1179/000349804225021343. PubMed: 15257793.
10. World Health Organization (WHO) (1993) implementation of the global malaria control strategy. Report of a WHO study group on the implementation of the global plan of action for malaria control, 1993-2000. Technical Report Series No. 839. Geneva
11. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R et al. (2000) Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 44: 1680-1685. doi: 10.1128/AAC.44.6.1680-1685.2000. PubMed: 10817728.
12. World Health Organization (WHO) (2010) Guidelines for the treatment of Malaria, 2nd ed. Geneva.
13. White NJ (2005) Intermittent presumptive treatment for malaria. PLoS Med 2: e3. doi:10.1371/journal.pmed.0020003. PubMed: 15696210.
14. Eastman RT, Fidock DA (2009) Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol 7: 864-874. PubMed: 19881520.
15. White NJ (1997) Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 41: 1413-1422. PubMed: 9210658.
16. Rijken MJ, McGready R, Phyo AP, Lindegardh N, Tarning J et al. (2011) Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and non-pregnant women with uncomplicated falciparum malaria. Antimicrob Agents Chemother 55: 5500-5506. doi:10.1128/AAC.05067-11. PubMed: 21947392.
17. Morris CA, Onyamboko MA, Capparelli E, Koch MA, Atibu J et al. (2011) Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria. Malar J 10: 114. doi:10.1186/1475-2875-10-114. PubMed: 21548983.
18. Myint HY, Ashley EA, Day NP, Nosten F, White NJ (2007) Efficacy and safety of dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg 101: 858-866. doi:10.1016/j.trstmh.2007.05.018. PubMed: 17659311.
19. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P, et al. (2009) Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev 8(3):CD007483. Available online at: doi:10.1002/14651858.CD007483.pub2
20. Naing C, Mak JW, Aung K, Wong JY (2013) Efficacy and safety of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in endemic countries: meta-analysis of randomized controlled studies. Trans R Soc Trop Med Hyg 107: 65-73. doi:10.1093/trstmh/trs019. PubMed: 23222952.
21. Carneiro I, Smith L, Ross A, Roca-Feltrer A, Greenwood B et al. (2010) Intermittent preventive treatment for malaria in infants: a decisionsupport tool for sub-Saharan Africa. Bull World Health Org 88: 807-811. doi:10.2471/BLT.09. 072397. PubMed: 21076561.
22. Gamage-Mendis AC, Rajakaruna J, Carter R, Mendis KN (1991) Infectious reservoir of plasmodium vivax and plasmodium falciparum malaria in an endemic region of Sri Lanka. Am J Trop Med Hyg 45: 479-487. PubMed: 1951856.
23. World Health Organization (WHO) (2009) Methods for surveillance of antimalarial drug efficacy. Available: http://whqlibdoc.who.int/publications/ 2009/9789241597531-eng.pdf. [Accessed 2013 June 10]
24. Higgins JPT, Green S (2011). Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available: www.cochranehandbook.org. [Accessed 2013 May 27]
25. Schunemann H, Brozek J, Oxman A, editors. (2009). GRADE handbook for grading quality of evidence and strength of recommendation, version 3.2 [updated March 2009]. The GRADE Working Group. Available: http://www.cc-ims.net/ gradepro. [Accessed 2013 June 12]
26. Parmar MKB, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834. doi:10.1002/(SICI)1097-0258(19981230)17:24. PubMed: 9921604.
27. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16. doi:10.1186/1745-6215-8-16. PubMed: 17555582.
28. PROSPERO International prospective register of systematic reviews (2013) Efficacy and safety of a fixed-dose dihydroartemisinin-piperaquine in treating uncomplicated Plasmodium vivax malaria: a systematic review and meta-analysis. CRD42013004625. Available: http://www.york.ac.uk/docs/disclaimer/email.htm. [Accessed 2013 June 2]
29. Moher D, Liberati A, Tetzlaff J, Altman DG, Grp P (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Medicine 6.
30. Ashley EA, McGready R, Hutagalung R, Phaiphun L, Slight T et al. (2005) A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis 41: 425-432. doi: 10.1086/432011. PubMed: 16028147.
31. Awab GR, Pukrittayakamee S, Imwong M, Dondorp AM, Woodrow CJ et al. (2010) Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority. Trial - Malar J 9: 105. doi:10.1186/1475-2875-9-105.
32. Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP et al. (2007) Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis 44: 1067-1074. doi:10.1086/512677. PubMed: 17366451.
33. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I et al. (2008) A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 11: 2545-2557.
34. Pasaribu AP, Chokejindachai W, Sirivichayakul C, Tanomsing N, Chavez I et al. (2013) A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatra, Indonesia. J Infect Dis. doi:10.1093/infdis/jit407.
35. Phyo AP, Lwin KM, Price RN, Ashley EA, Russell B et al. (2011) Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax Malaria in Thailand: A randomized controlled trial. Clin Infect Dis 53: 977-984. doi:10.1093/cid/cir631. PubMed: 22002979.
36. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM et al. (2007) A Two fixed dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomized comparison. Lancet 369: 757-765. doi:10.1016/S0140-6736(07)60160-3. PubMed: 17336652.
37. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP et al. (2010) Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomized trial. Lancet Infect Dis 10: 673-681. doi:10.1016/S1473-3099(10)70187-0. PubMed: 20832366.
38. Tjitra E, Hasugian AR, Siswantoro H, Prasetyorini B, Ekowatiningsih R et al. (2012) Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia. Malar J 11: 153. doi: 10.1186/1475-2875-11-153. PubMed: 22554203.
39. Karunajeewa HA, Ilett KF, Dufall K, Kemiki A, Bockarie M et al. (2004) Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria. Antimicrob Agents Chemother 48: 2966-2972. doi:10.1128/AAC.48.8.2966- 2972.2004. PubMed: 15273107.
40. Zwang J, Ashley EA, Karema C, D'Alessandro U, Smithuis F et al. (2009) Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLOS ONE 4: e6358. doi:10.1371/journal.pone.0006358. PubMed: 19649267.
41. Mayxay M, Keomany S, Khanthavong M, Souvannasing P, Stepniewska K et al. (2010) A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in Southern Laos. Am J Trop Med Hyg 83: 1221-1229. doi:10.4269/ajtmh. 2010.10-0276. PubMed: 21118925.
42. Hung T-Y, Davis TME, Ilett KF, Karunajeewa H, Hewitt S et al. (2004) Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol 57: 253-262. PubMed: 14998421.
43. Leang R, Barrette A, Bouth DM, Menard D, Abdur R et al. (2013) Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother 57: 818-826. doi:10.1128/AAC.00686-12. PubMed: 23208711.
44. Douglas NM, Nosten F, Ashley EA, Phaiphun L, van Vugt M et al. (2011) Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis 52: 612-620. doi:10.1093/cid/ciq249. PubMed: 21292666.
45. Lwin KM, Phyo AP, Tarning J, Hanpithakpong W, Ashley EA et al. (2012) Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria. Antimicrob Agents Chemother 56: 1571-1577. doi:10.1128/AAC.05877-11. PubMed: 22252804.
46. Leslie T, Mayan MI, Hasan MA, Safi MH, Klinkenberg E (2007) Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial. JAMA 297: 2201-2209. doi: 10.1001/jama.297.20.2201. PubMed: 17519409.
47. World Health Organization (WHO) (2008) Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Geneva: World Health Organization. Available: http://www.who.int/ malaria/resistance. [Accessed 2013 August 9]
48. Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q (2007) Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J Infect Dis 195: 934-941. doi: 10.1086/512242. PubMed: 17330782.
49. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR et al. (2007) Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 195: 927-933. doi: 10.1086/512241. PubMed: 17330781.
50. Collins WE, Jeffery GM (1996) Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg 55: 243-249. PubMed: 8842108.
51. White NJ (2002) The assessment of antimalarial drug efficacy. Trends Parasitol 18: 458-464. doi:10.1016/S1471-4922(02)02373-5. PubMed: 12377597.
52. Tarning J, Zongo I, Somé FA, Rouamba N, Parikh S et al. (2012) Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther 91: 497-505. doi:10.1038/clpt.2011.254. PubMed: 22258469.
53. White NJ (2011) Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J 10: 297. doi:10.1186/1475-2875-10-297. PubMed: 21989376.
54. Katz MH (1999) Multivariate analysis: a practical guide for clinicians. New York: Cambridge University Press.
55. Spruance SL, Reid JE, Grace M, Samore M (2004) Hazard ratio in clinical trials. Antimicrob Agents Chemother 48: 2787-2792. PubMed: 15273082.
56. Na-Bangchang K, Ruengweerayut R, Mahamad P, Ruengweerayut K, Chaijaroenkul W (2010) Declining in efficacy of a three-day combination regimen of mefloquine artesunate in a multi-drug resistance area along the Thai-Myanmar border. Malar J 9: 273. doi: 10.1186/1475-2875-9-273. PubMed: 20929590.
57. Jansen FH (2010) The pharmaceutical death-ride of dihydroartemisinin. Malar J 9: 212. doi:10.1186/1475-2875-9-212. PubMed: 20649950.
58. Stepniewska K, Taylor WR, Mayxay M, Price R, Smithuis F et al. (2004) In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother 48: 4271-4280. doi:10.1128/AAC.48.11. 4271-4280.2004. PubMed: 15504852.
59. Borsini F, Crumb W, Pace S, Ubben D, Wible B et al. (2012) In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials. Antimicrob Agents Chemother 56: 3261-3270. doi:10.1128/AAC.05688-11. PubMed: 22391528.